Tiumbio Showcases Promising Clinical Results for Novel Cancer Drug at SITC 2025 Tiumbio Co., Ltd. revealed exciting interim Phase II clinical results for Tosposertib at SITC 2025, showcasing impressive response rates.

Tiumbio Showcases Promising Clinical Results for Novel Cancer Drug at SITC 2025 #South_Korea #Seongnam #TiumBio #Tosposertib #SITC2025